









Markets
/
Stocks
/
nasdaq-gild
/

Gilead Sciences Inc

GILD

118.440USD

-0.060-0.05%

Close 10/30, 16:00（ET）Quotes delayed by 15 min

147.10BMarket Cap

23.31P/E TTM



Gilead Sciences Inc

118.440

-0.060-0.05%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Gilead Sciences Inc

Currency: USD Updated: 2025-10-29

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The company is performing well in the stock market, with strong fundamentals and technicals supporting the current trend. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Gilead Sciences Inc's Score

Industry at a Glance

Industry Ranking

4 / 160

Overall Ranking

22 / 4623

Industry

Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 30 analysts

Buy

Current Rating

127.172

Target Price

+7.88%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Gilead Sciences Inc Highlights

StrengthsRisks

Gilead Sciences, Inc. is a biopharmaceutical company. It is engaged in advancing medicines to prevent and treat life-threatening diseases, including human immunodeficiency virus (HIV), viral hepatitis, coronavirus disease 2019 (COVID-19) and cancer. It is focused on the discovery, development and commercialization of medicines in areas of unmet medical need. Its portfolio of marketed products includes AmBisome, Atripla, Biktarvy, Cayston, Complera, Descovy, Descovy for PrEP, Emtriva, Epclusa, Eviplera, Genvoya, Harvoni, Hepcludex, Hepsera, Jyseleca, Letairis, Odefsey, Sovaldi, Stribild, Sunlenca, Tecartus, Trodelvy, Truvada, Truvada for PrEP, Tybost, Veklury, Vemlidy, Viread, Vosevi, Yescarta and Zydelig. Its product candidates include Bulevirtide, Lenacapavir, Axicabtagene ciloleucel, and Domvanalimab and zimberelimab, and seladelpar. Seladelpar shall be used for the treatment of primary biliary cholangitis (PBC), including pruritus. The Company operates in more than 35 countries.

High Dividend

The company is a high dividend payer, with the latest dividend payout ratio of 814.79%.

Stable Dividend

The company has regularly paid dividends over the past 5 years, with the latest dividend payout ratio of 814.79%.

Overvalued

The company’s latest PE is 23.40, at a high 3-year percentile range.

Fairly Valued

The company’s latest PE is 23.40, at a medium 3-year percentile range.

Institutional Buying

The latest institutional holdings are 1.13B shares, increasing 0.38% quarter-over-quarter.

Held by Van Duyn Dodge & E. Morris Cox

Star Investor Van Duyn Dodge & E. Morris Cox holds 30.82M shares of this stock.

Financial Health

Currency: USD Updated: 2025-10-29

The company's current financial score is 8.34, which is higher than the Pharmaceuticals industry's average of 7.76. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 7.08B, representing a year-over-year increase of 1.84%, while its net profit experienced a year-over-year increase of 21.44%.

Score

Industry at a Glance

Previous score

8.34

Change



Financials

6.13

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.44

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

8.11

Key Metrics

Free cash flow

No Data

Gilead Sciences Inc's Company Valuation

Currency: USD Updated: 2025-10-29

The company’s current valuation score is 7.64, which is higher than the Pharmaceuticals industry's average of 7.22. Its current P/E ratio is 23.40, which is 3967.37% below the recent high of 951.96 and 33.37% above the recent low of 15.60.

Score

Industry at a Glance

Previous score

7.64

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 4/160

No Data

Earnings Forecast

Currency: USD Updated: 2025-10-29

The company’s current earnings forecast score is 8.07, which is higher than the Pharmaceuticals industry's average of 7.79. The average price target for Gilead Sciences Inc is 131.00, with a high of 143.00 and a low of 100.00.

Score

Industry at a Glance

Previous score

8.07

Change

Support & Resistance

No Data

Analyst Rating

Based on 30 analysts

Buy

Current Rating

127.172

Target Price

+7.32%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

169

Total

Median

Average

Company name

Ratings

Analysts

Gilead Sciences Inc

GILD

Biogen Inc

BIIB

Amgen Inc

AMGN

Vertex Pharmaceuticals Inc

VRTX

AbbVie Inc

ABBV

Eli Lilly and Co

LLY

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-10-29

The company’s current price momentum score is 9.04, which is higher than the Pharmaceuticals industry's average of 6.80. Sideways: Currently, the stock price is trading between the resistance level at 125.92 and the support level at 109.77, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

8.86

Change

0.18

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(3)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.678

Neutral

RSI(14)

51.620

Neutral

STOCH(KDJ)(9,3,3)

24.199

Sell

ATR(14)

2.907

Low Volatility

CCI(14)

-47.649

Neutral

Williams %R

70.034

Sell

TRIX(12,20)

0.250

Sell

StochRSI(14)

15.798

Oversold

Moving Average

Sell(3)

Neutral(0)

Buy(3)

Indicators

Value

Direction

MA5

119.246

Sell

MA10

120.843

Sell

MA20

118.824

Sell

MA50

115.618

Buy

MA100

113.980

Buy

MA200

109.685

Buy

Institutional Confidence

Currency: USD Updated: 2025-10-29

The company’s current institutional recognition score is 10.00, which is higher than the Pharmaceuticals industry's average of 5.79. The latest institutional shareholding proportion is 90.97%, representing a quarter-over-quarter increase of 1.07%. The largest institutional shareholder is The Vanguard, holding a total of 118.78M shares, representing 9.57% of shares outstanding, with 3.75% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

The Vanguard Group, Inc.

Star Investors

118.78M

+1.60%

BlackRock Institutional Trust Company, N.A.

70.80M

+0.20%

State Street Investment Management (US)

59.19M

-0.56%

Fidelity Management & Research Company LLC

53.76M

+4.98%

Capital World Investors

46.30M

-13.53%

Wellington Management Company, LLP

37.53M

+37.18%

Capital Research Global Investors

31.10M

-43.06%

Dodge & Cox

Star Investors

30.82M

-5.74%

Geode Capital Management, L.L.C.

29.21M

+2.55%

Invesco Capital Management (QQQ Trust)

25.46M

-0.35%

Risk Assessment

Currency: USD Updated: 2025-10-29

The company’s current risk assessment score is 9.06, which is higher than the Pharmaceuticals industry's average of 5.13. The company's beta value is 0.33. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.